Derek Archila
Stock Analyst at Wells Fargo
(4.39)
# 322
Out of 5,163 analysts
229
Total ratings
52.87%
Success rate
17.41%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $136 → $143 | $87.38 | +63.65% | 9 | Mar 12, 2026 | |
| SEPN Septerna | Maintains: Overweight | $28 → $48 | $25.14 | +90.93% | 6 | Mar 3, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $78 → $79 | $60.04 | +31.58% | 3 | Mar 2, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $1,317 → $1,247 | $700.45 | +78.03% | 16 | Feb 27, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $114 → $110 | $33.76 | +225.88% | 4 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $88 → $98 | $69.41 | +41.19% | 3 | Feb 13, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $107 → $101 | $92.54 | +9.14% | 13 | Feb 11, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $26 → $29 | $28.68 | +1.12% | 3 | Feb 3, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $30 → $29 | $15.04 | +92.82% | 8 | Jan 29, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $322 → $330 | $225.98 | +46.03% | 16 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $26 | $18.94 | +37.28% | 14 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $479 → $376 | $313.41 | +19.97% | 2 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $30 | $16.02 | +87.27% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $39 | $24.81 | +57.19% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $8.95 | +268.72% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $79.03 | +46.78% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $11.90 | +110.08% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $5.66 | +377.03% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $12.18 | +23.15% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $64.81 | +24.98% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $41.24 | -27.26% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.85 | -27.01% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.72 | +267.65% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.85 | +17.65% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $29.51 | +28.77% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $23.08 | +29.98% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $3.06 | -34.64% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $2.71 | +84.50% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $6.82 | +119.94% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $22.88 | -38.81% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $24.41 | +84.35% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.44 | +719.67% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.99 | +200.50% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.71 | +508.64% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $85.36 | -51.97% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.34 | +943.02% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $20.58 | +191.55% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $8.81 | +229.17% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $0.88 | +5,570.86% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $18.45 | +176.42% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $9.30 | +846.24% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.26 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $28.57 | - | 2 | Aug 3, 2017 |
Rhythm Pharmaceuticals
Mar 12, 2026
Maintains: Overweight
Price Target: $136 → $143
Current: $87.38
Upside: +63.65%
Septerna
Mar 3, 2026
Maintains: Overweight
Price Target: $28 → $48
Current: $25.14
Upside: +90.93%
Disc Medicine
Mar 2, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $60.04
Upside: +31.58%
argenx SE
Feb 27, 2026
Maintains: Overweight
Price Target: $1,317 → $1,247
Current: $700.45
Upside: +78.03%
Soleno Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $114 → $110
Current: $33.76
Upside: +225.88%
BridgeBio Pharma
Feb 13, 2026
Maintains: Overweight
Price Target: $88 → $98
Current: $69.41
Upside: +41.19%
Incyte
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $107 → $101
Current: $92.54
Upside: +9.14%
Viridian Therapeutics
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $28.68
Upside: +1.12%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $15.04
Upside: +92.82%
Ascendis Pharma
Jan 20, 2026
Maintains: Overweight
Price Target: $322 → $330
Current: $225.98
Upside: +46.03%
Jan 20, 2026
Maintains: Overweight
Price Target: $29 → $26
Current: $18.94
Upside: +37.28%
Jan 20, 2026
Maintains: Equal-Weight
Price Target: $479 → $376
Current: $313.41
Upside: +19.97%
Jan 8, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $16.02
Upside: +87.27%
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $24.81
Upside: +57.19%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $8.95
Upside: +268.72%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $79.03
Upside: +46.78%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $11.90
Upside: +110.08%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $5.66
Upside: +377.03%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $12.18
Upside: +23.15%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $64.81
Upside: +24.98%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $41.24
Upside: -27.26%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.85
Upside: -27.01%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.72
Upside: +267.65%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.85
Upside: +17.65%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $29.51
Upside: +28.77%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $23.08
Upside: +29.98%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $3.06
Upside: -34.64%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $2.71
Upside: +84.50%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $6.82
Upside: +119.94%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $22.88
Upside: -38.81%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $24.41
Upside: +84.35%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.44
Upside: +719.67%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $5.99
Upside: +200.50%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.71
Upside: +508.64%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $85.36
Upside: -51.97%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.34
Upside: +943.02%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $20.58
Upside: +191.55%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $8.81
Upside: +229.17%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $0.88
Upside: +5,570.86%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $18.45
Upside: +176.42%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $9.30
Upside: +846.24%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.26
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $28.57
Upside: -